CD30/CD30 Ligand and CD40/CD40 Ligand in Malignant Lymphoid Disorders-Reference-Cited by-同舟云学术

CD30/CD30 Ligand and CD40/CD40 Ligand in Malignant Lymphoid Disorders

Published:1999-07 Issue:3 Volume:14 Page:135-143
ISSN:1724-6008
Container-title:The International Journal of Biological Markers
language:en
Short-container-title:Int J Biol Markers

Author:

Younes A.¹,Carbone A.²

Affiliation:

1. Department of Lymphoma, U.T. M.D. Anderson Cancer Center, Houston, Texas - U.S.A.

2. Division of Pathology, Centro di Riferimento Oncologico, Istituto Nazionale Tumori, Aviano - Italy

Abstract

CD30 and CD40 are members of the tumor necrosis factor (TNF) receptor family. These two receptors have pleiotropic biologic functions including induction of apoptosis and enhancing cell survival. This review will discuss the pattern of expression of these receptors in malignant lymphoid disorders and their prospective ligands. Understanding issues related to these two ligands and their receptors in lymphoid malignancies may help to improve the classification of these diseases and could open the doors for new treatment strategies.

Publisher

SAGE Publications

Subject

Cancer Research,Clinical Biochemistry,Oncology,Pathology and Forensic Medicine

Link

http://journals.sagepub.com/doi/pdf/10.1177/172460089901400303

Reference115 articles.

1. Evidence for the detection of the normal counterpart of hodgkin and sternberg-reed cells

2. Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease

3. CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF

4. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells

5. Activation of human B cells mediated through two distinct cell surface differentiation antigens, Bp35 and Bp50.

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tackling the dysregulated immune-checkpoints in classical Hodgkin lymphoma: bidirectional regulations between the microenvironment and Hodgkin/Reed-Sternberg cells;Frontiers in Oncology;2023-05-24

2. Fate of Antibody-Drug Conjugates in Cancer Cells;Journal of Experimental & Clinical Cancer Research;2018-02-06

3. Brentuximab vedotin. an antibody-drug conjugate targeting CD30;Drug Delivery System;2017

4. Bewährte Strategien und neue Ansätze;Im Focus Onkologie;2015-02

5. Clinical Options in Relapsed or Refractory Hodgkin Lymphoma: An Updated Review;Journal of Immunology Research;2015